Next Article in Journal
Data Integration for Microarrays: Enhanced Inference for Gene Regulatory Networks
Previous Article in Journal
Label and Label-Free Detection Techniques for Protein Microarrays
Previous Article in Special Issue
Tissue Microarray Technology for Molecular Applications: Investigation of Cross-Contamination between Tissue Samples Obtained from the Same Punching Device
Article Menu

Export Article

From the third issue of 2017, Microarrays has changed its name to High-Throughput.

Open AccessArticle

Re-Punching Tissue Microarrays Is Possible: Why Can This Be Useful and How to Do It

Molecular Pathology Division, Institute of Pathology, University Hospital of Basel, CH-4031 Basel, Switzerland
Author to whom correspondence should be addressed.
Academic Editor: Luigi Terracciano
Microarrays 2015, 4(2), 245-254;
Received: 15 February 2015 / Revised: 25 April 2015 / Accepted: 29 April 2015 / Published: 11 May 2015
PDF [6878 KB, uploaded 11 May 2015]


Tissue microarray (TMA) methodology allows the concomitant analysis of hundreds of tissue specimens arrayed in the same manner on a recipient block. Subsequently, all samples can be processed under identical conditions, such as antigen retrieval procedure, reagent concentrations, incubation times with antibodies/probes, and escaping the inter-assays variability. Therefore, the use of TMA has revolutionized histopathology translational research projects and has become a tool very often used for putative biomarker investigations. TMAs are particularly relevant for large scale analysis of a defined disease entity. In the course of these exploratory studies, rare subpopulations can be discovered or identified. This can refer to subsets of patients with more particular phenotypic or genotypic disease with low incidence or to patients receiving a particular treatment. Such rare cohorts should be collected for more specific investigations at a later time, when, possibly, more samples of a rare identity will be available as well as more knowledge derived from concomitant, e.g., genetic, investigations will have been acquired. In this article we analyze for the first time the limits and opportunities to construct new TMA blocks using tissues from older available arrays and supplementary donor blocks. In summary, we describe the reasons and technical details for the construction of rare disease entities arrays. View Full-Text

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Lacombe, A.; Carafa, V.; Schneider, S.; Sticker-Jantscheff, M.; Tornillo, L.; Eppenberger-Castori, S. Re-Punching Tissue Microarrays Is Possible: Why Can This Be Useful and How to Do It. Microarrays 2015, 4, 245-254.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics



[Return to top]
Microarrays EISSN 2076-3905 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top